Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth

被引:0
|
作者
Nicole Schreiber-Agus
Yong Meng
Tin Hoang
Harry Hou
Ken Chen
Roger Greenberg
Carlos Cordon-Cardo
Han-Woong Lee
Ronald A. DePinho
机构
[1] Departments of Molecular Genetics,Department of Biochemistry and Molecular Biology
[2] Microbiology and Immunology,undefined
[3] Albert Einstein College of Medicine,undefined
[4] Memorial Sloan-Kettering Cancer Center,undefined
[5] Ilchun Institute for Molecular Medicine,undefined
[6] Seoul National University College of Medicine,undefined
来源
Nature | 1998年 / 393卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Mxi1 belongs to the Mad (Mxi1) family of proteins, which function as potent antagonists of Myc oncoproteins1,2,3,4. This antagonism relates partly to their ability to compete with Myc for the protein Max and for consensus DNA binding sites and to recruit transcriptional co-repressors4,5,6. Mad(Mxi1) proteins have been suggested to be essential in cellular growth control and/or in the induction and maintenance of the differentiated state6,7. Consistent with these roles, mxi1 may be the tumour-suppressor gene that resides at region 24–26 of the long arm of chromosome 10. This region is a cancer hotspot, and mutations here may be involved in several cancers, including prostate adenocarcinoma8,9,10. Here we show that mice lacking Mxi1 exhibit progressive, multisystem abnormalities. These mice also show increased susceptibility to tumorigenesis either following carcinogen treatment or when also deficient in Ink4a. This cancer-prone phenotype may correlate with the enhanced ability of several mxi1-deficient cell types, including prostatic epithelium, to proliferate. Our results show that Mxi1 is involved in the homeostasis of differentiated organ systems, acts as a tumour suppressor in vivo, and engages the Myc network in a functionally relevant manner.
引用
收藏
页码:483 / 487
页数:4
相关论文
共 50 条
  • [31] Transgenic mouse models for studies of the role of polyamines in normal, hypertrophic and neoplastic growth
    Pegg, AE
    Feith, DJ
    Fong, LYY
    Coleman, CS
    O'Brien, TG
    Shantz, LM
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2003, 31 : 356 - 360
  • [32] DESMOSTEROL IN RAT CENTRAL AND PERIPHERAL NERVOUS SYSTEMS DURING NORMAL AND NEOPLASTIC GROWTH
    WEISS, JF
    CRAVIOTO, H
    RANSOHOFF, J
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1975, 54 (03) : 781 - 783
  • [33] Role of Oxytocin/Oxytocin Receptor System in Regulation of Cell Growth and Neoplastic Processes
    Strunecka, A.
    Hynie, S.
    Klenerova, V.
    FOLIA BIOLOGICA, 2009, 55 (05) : 159 - 165
  • [34] Role of SIRT1 in the growth and regulation of normal hematopoietic and leukemia stem cells
    Li, Ling
    Bhatia, Ravi
    CURRENT OPINION IN HEMATOLOGY, 2015, 22 (04) : 324 - 329
  • [35] INSULIN, EGF AND GLUCOCORTICOIDS IN THE REGULATION OF GROWTH IN NORMAL AND NEOPLASTIC HUMAN PROSTATIC EPITHELIAL-CELLS
    WEBBER, MM
    CHAPRONIERERICKENBERG, DM
    DONOHUE, RE
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1983, 24 (MAR): : 182 - 182
  • [36] REGULATORY ROLE OF MEVALONATE IN THE GROWTH OF NORMAL AND NEOPLASTIC HUMAN MAMMARY EPITHELIAL-CELLS
    LARSSON, O
    BLEGEN, H
    ANTICANCER RESEARCH, 1993, 13 (04) : 1075 - 1080
  • [37] DIFFERENTIAL REGULATION OF PLASMINOGEN ACTIVATORS BY EPIDERMAL GROWTH-FACTOR IN NORMAL AND NEOPLASTIC HUMAN UROTHELIUM
    DUBEAU, L
    JONES, PA
    RIDEOUT, WM
    LAUG, WE
    CANCER RESEARCH, 1988, 48 (19) : 5552 - 5556
  • [38] Self-regulation in tip-growth: The role of cell wall ageing
    Eggen, Eelco
    de Keijzer, M. Niels
    Mulder, Bela M.
    JOURNAL OF THEORETICAL BIOLOGY, 2011, 283 (01) : 113 - 121
  • [39] The role of the quantitative factor in alteration of population functional status during normal and neoplastic growth
    Shabalkin, IP
    Yagubov, AS
    Mamontov, SG
    Shabalkin, PI
    DOKLADY AKADEMII NAUK, 1999, 365 (04) : 561 - 567
  • [40] PLASMINOGEN-ACTIVATOR REGULATION BY TRANSFORMING GROWTH-FACTOR-BETA IN NORMAL AND NEOPLASTIC HUMAN UROTHELIUM
    HITI, AL
    RIDEOUT, WM
    LAUG, WE
    JONES, PA
    CANCER COMMUNICATIONS, 1990, 2 (03): : 123 - 128